Insider Buying: EuroEyes International Eye Clinic Founder Bought HK$448k Of Shares
Insider Buying: EuroEyes International Eye Clinic Founder Bought HK$448k Of Shares
Even if it's not a huge purchase, we think it was good to see that Jörn Jörgensen, the Founder of EuroEyes International Eye Clinic Limited (HKG:1846) recently shelled out HK$448k to buy stock, at HK$4.39 per share. Nevertheless, it only increased their shareholding by a minuscule percentage, and it wasn't a massive purchase by absolute value, either.
即使这不是一笔大笔收购,我们也认为很高兴看到该公司的创始人约恩·约尔根森 EuroEyes 国际眼科诊所有限公司 (HKG: 1846)最近以每股4.39港元的价格出资44.8万港元购买股票。尽管如此,它只增加了微不足道的股权,按绝对价值计算,这也不是一笔大规模的收购。
See our latest analysis for EuroEyes International Eye Clinic
查看我们对 EuroEyes 国际眼科诊所的最新分析
EuroEyes International Eye Clinic Insider Transactions Over The Last Year
EuroEyes 国际眼科诊所去年内幕交易
Notably, that recent purchase by Founder Jörn Jörgensen was not the only time they bought EuroEyes International Eye Clinic shares this year. Earlier in the year, they paid HK$5.50 per share in a HK$4.4m purchase. That means that an insider was happy to buy shares at above the current price of HK$4.40. Their view may have changed since then, but at least it shows they felt optimistic at the time. To us, it's very important to consider the price insiders pay for shares. It is generally more encouraging if they paid above the current price, as it suggests they saw value, even at higher levels.
值得注意的是,创始人约恩·约尔根森最近的收购并不是他们今年唯一一次购买EuroEyes International Eye Clinic的股票。今年早些时候,他们以每股5.50港元的价格收购了440万港元。这意味着内部人士乐于以高于当前4.40港元的价格购买股票。从那以后,他们的看法可能发生了变化,但至少这表明他们当时感到乐观。对我们来说,考虑内部人士为股票支付的价格非常重要。如果他们支付的费用高于当前价格,通常会更令人鼓舞,因为这表明即使在更高的水平上,他们也看到了价值。
In the last twelve months EuroEyes International Eye Clinic insiders were buying shares, but not selling. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. By clicking on the graph below, you can see the precise details of each insider transaction!
在过去的十二个月中,EuroEyes International Eye Clinic的内部人士在买入股票,但没有卖出您可以在下面看到过去 12 个月内幕交易(公司和个人)的直观描述。点击下图,你可以看到每笔内幕交易的确切细节!
EuroEyes International Eye Clinic is not the only stock that insiders are buying. For those who like to find winning investments this free list of growing companies with recent insider purchasing, could be just the ticket.
EuroEyes International Eye Clinic并不是业内人士唯一购买的股票。对于那些喜欢寻找的人 获胜的投资 这个 免费的 最近进行内幕收购的成长型公司名单可能只是门票。
Does EuroEyes International Eye Clinic Boast High Insider Ownership?
EuroEyes国际眼科诊所是否拥有很高的内部所有权?
For a common shareholder, it is worth checking how many shares are held by company insiders. I reckon it's a good sign if insiders own a significant number of shares in the company. It's great to see that EuroEyes International Eye Clinic insiders own 57% of the company, worth about HK$836m. This kind of significant ownership by insiders does generally increase the chance that the company is run in the interest of all shareholders.
对于普通股股东来说,值得检查一下公司内部人士持有多少股票。我认为,如果内部人士拥有该公司的大量股份,那将是一个好兆头。很高兴看到EuroEyes International Eye Clinic的内部人士拥有该公司57%的股份,价值约8.36亿港元。内部人士的这种重要所有权通常会增加公司为所有股东的利益而经营的机会。
So What Does This Data Suggest About EuroEyes International Eye Clinic Insiders?
那么,这些数据对EuroEyes国际眼科诊所内部人士有什么启示?
The recent insider purchase is heartening. And an analysis of the transactions over the last year also gives us confidence. Once you factor in the high insider ownership, it certainly seems like insiders are positive about EuroEyes International Eye Clinic. That's what I like to see! If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
最近的内幕收购令人振奋。对去年交易的分析也给了我们信心。一旦你将内部人士的高所有权考虑在内,内部人士似乎对EuroEyes International Eye Clinic持乐观态度。这就是我喜欢看到的!如果你像我一样,你可能需要考虑这家公司是增长还是萎缩。幸运的是,你可以看看这个 免费的 报告显示了分析师对其未来的预测。
If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.
如果你想去另一家公司看看 —— 一家财务状况可能优异的公司 —— 那千万不要错过这个 免费的 股本回报率高、债务低的有趣公司名单。
For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.
就本文而言,内部人士是指向相关监管机构报告其交易的个人。我们目前只考虑公开市场交易和私下处置的直接利益,不包括衍生品交易或间接权益。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对这篇文章有反馈吗?担心内容吗? 取得联系 直接和我们在一起。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。 我们仅使用公正的方法根据历史数据和分析师的预测提供评论,我们的文章无意作为财务建议。 它不构成买入或卖出任何股票的建议,也没有考虑您的目标或财务状况。我们的目标是为您提供由基本面数据驱动的长期重点分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。简而言之,华尔街在上述任何股票中都没有头寸。